iBio, Inc. Common Stock (IBIO) is a publicly traded Healthcare sector company. As of May 21, 2026, IBIO trades at $1.71 with a market cap of $70.54M and a P/E ratio of -3.01. IBIO moved +14.67% today. Year to date, IBIO is -9.57%; over the trailing twelve months it is +107.11%. Its 52-week range spans $0.56 to $6.89. Analyst consensus is strong buy with an average price target of $5.80. Rallies surfaces IBIO's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
iBio Secures Phase 1 IBIO-600 Clearance, IBIO-610 Cuts Visceral Fat by 6.7%: iBio secured TGA approval to begin a Phase 1 trial of IBIO-600 in obese adults and expanded its pipeline with a bispecific antibody for PH-HFpEF. Preclinical IBIO-610 NHP data showed 6.7% visceral and 5.2% total fat reduction; cash of $74.8 million plus $17 million from warrants extends runway into Q4 FY2028.
| Metric | Value |
|---|---|
| Price | $1.71 |
| Market Cap | $70.54M |
| P/E Ratio | -3.01 |
| EPS | $-0.56 |
| Dividend Yield | 0.00% |
| 52-Week High | $6.89 |
| 52-Week Low | $0.56 |
| Volume | 1.19K |
| Avg Volume | 0 |
| Revenue (TTM) | $300.00K |
| Net Income | $-27.61M |
| Gross Margin | 0.00% |
5 analysts cover IBIO: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $5.80.